Oppenheimer & Co’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$23.4M Buy
831,613
+136,995
+20% +$3.65M 0.28% 59
2025
Q4
$17.3M Sell
694,618
-8,787
-1% -$222K 0.25% 81
2025
Q3
$17.9M Buy
703,405
+61,829
+10% +$1.53M 0.22% 92
2025
Q2
$15.6M Buy
641,576
+5,361
+0.8% +$125K 0.21% 100
2025
Q1
$16.1M Buy
636,215
+54,844
+9% +$1.44M 0.24% 77
2024
Q4
$15.4M Sell
581,371
-77,017
-12% -$2.09M 0.23% 80
2024
Q3
$19.1M Buy
658,388
+53,526
+9% +$1.56M 0.29% 67
2024
Q2
$16.9M Sell
604,862
-2,490
-0.4% -$68.6K 0.27% 73
2024
Q1
$16.9M Buy
607,352
+96,110
+19% +$2.67M 0.28% 72
2023
Q4
$14.7M Sell
511,242
-138,238
-21% -$4.18M 0.27% 74
2023
Q3
$21.5M Sell
649,480
-51,337
-7% -$1.82M 0.44% 36
2023
Q2
$25.7M Buy
700,817
+16,798
+2% +$654K 0.51% 28
2023
Q1
$27.9M Buy
684,019
+30,836
+5% +$1.33M 0.59% 20
2022
Q4
$33.5M Sell
653,183
-15,586
-2% -$747K 0.76% 13
2022
Q3
$29.3M Sell
668,769
-38,012
-5% -$1.85M 0.68% 15
2022
Q2
$37.1M Sell
706,781
-39,917
-5% -$2.03M 0.8% 13
2022
Q1
$38.7M Buy
746,698
+16,731
+2% +$868K 0.7% 17
2021
Q4
$43.1M Buy
729,967
+52,501
+8% +$2.6M 0.75% 16
2021
Q3
$29.1M Buy
677,466
+2,647
+0.4% +$117K 0.55% 22
2021
Q2
$26.4M Buy
674,819
+20,242
+3% +$787K 0.47% 27
2021
Q1
$23.7M Sell
654,577
-9,293
-1% -$330K 0.47% 28
2020
Q4
$24.4M Sell
663,870
-13,970
-2% -$512K 0.52% 29
2020
Q3
$23.6M Sell
677,840
-45,071
-6% -$1.58M 0.59% 26
2020
Q2
$22.4M Sell
722,911
-126,002
-15% -$4.28M 0.58% 30
2020
Q1
$26.3M Buy
848,913
+37,066
+5% +$1.26M 0.8% 18
2019
Q4
$30.2M Buy
811,847
+15,664
+2% +$558K 0.75% 16
2019
Q3
$27.1M Sell
796,183
-6,720
-0.8% -$244K 0.74% 18
2019
Q2
$33M Sell
802,903
-29,993
-4% -$1.19M 0.9% 11
2019
Q1
$33.6M Buy
832,896
+23,541
+3% +$943K 0.9% 13
2018
Q4
$33.5M Sell
809,355
-16,279
-2% -$676K 1.05% 7
2018
Q3
$34.5M Buy
825,634
+12,889
+2% +$496K 0.88% 11
2018
Q2
$28M Buy
812,745
+51,863
+7% +$1.77M 0.76% 16
2018
Q1
$25.6M Buy
760,882
+13,420
+2% +$461K 0.66% 19
2017
Q4
$25.7M Buy
747,462
+22,961
+3% +$783K 0.66% 24
2017
Q3
$24.5M Sell
724,501
-33,423
-4% -$1.07M 0.66% 23
2017
Q2
$24.2M Sell
757,924
-33,168
-4% -$1.05M 0.67% 21
2017
Q1
$25.7M Sell
791,092
-1,386
-0.2% -$43.7K 0.73% 18
2016
Q4
$24.4M Buy
792,478
+20,150
+3% +$615K 0.71% 15
2016
Q3
$24.8M Sell
772,328
-32,208
-4% -$1.08M 0.72% 14
2016
Q2
$26.9M Sell
804,536
-44,899
-5% -$1.43M 0.8% 14
2016
Q1
$23.9M Buy
849,435
+12,639
+2% +$361K 0.73% 16
2015
Q4
$25.6M Buy
836,796
+11,113
+1% +$350K 0.76% 13
2015
Q3
$24.6M Buy
825,683
+38,573
+5% +$1.24M 0.75% 13
2015
Q2
$25M Sell
787,110
-6,107
-0.8% -$199K 0.7% 12
2015
Q1
$26.2M Sell
793,217
-17,715
-2% -$563K 0.71% 13
2014
Q4
$24M Buy
810,932
+37,653
+5% +$1.08M 0.69% 15
2014
Q3
$21.7M Sell
773,279
-35,542
-4% -$998K 0.65% 20
2014
Q2
$22.8M Sell
808,821
-45,416
-5% -$1.29M 0.69% 19
2014
Q1
$26M Buy
854,237
+55,890
+7% +$1.67M 0.78% 12
2013
Q4
$23.2M Sell
798,347
-53,838
-6% -$1.57M 0.74% 13
2013
Q3
$23.2M Buy
852,185
+253
+0% +$6.88K 0.82% 10
2013
Q2
$22.6M Buy
+851,932
New +$23.5M 0.88% 8

Other funds holding PFE

Oppenheimer & Co's PFE Position: Q1 2026 in Review

Oppenheimer & Co increased its Pfizer (PFE) stake by 20% in Q1 2026, buying an estimated $3.65M and bringing the position to 831,613 shares worth $23.4M. The position accounts for 0.28% of the portfolio, ranked #59.

Oppenheimer & Co first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $43.1M in Q4 2021. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Oppenheimer & Co held 831,613 shares of Pfizer worth $23.4M as of Q1 2026.
  • Oppenheimer & Co bought 136,995 Pfizer shares in Q1 2026, an estimated $3.65M.
  • Pfizer made up 0.28% of Oppenheimer & Co's portfolio in Q1 2026, its #59 holding.
  • Oppenheimer & Co first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Oppenheimer & Co's Pfizer position peaked at $43.1M in Q4 2021.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.